Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer

Sanne C. F. A. Huijberts*, Robin M. J. M. van Geel, Emilie M. J. van Brummelen, Frans L. Opdam*, Serena Marchetti, Neeltje Steeghs, Saskia Pulleman, Bas Thijssen, Hilde Rosing, Kim Monkhorst, Alwin D. R. Huitema, Jos H. Beijnen, Rene Bernards, Jan H. M. Schellens

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)917-930
Number of pages14
JournalCancer Chemotherapy and Pharmacology
Volume85
Issue number5
DOIs
Publication statusPublished - May 2020

Keywords

  • Lapatinib
  • Trametinib
  • KRAS mutation
  • Phase I
  • MEK INHIBITOR TRAMETINIB
  • TYROSINE KINASE INHIBITOR
  • DOSE-ESCALATION
  • COLON-CANCER
  • GROWTH
  • MULTICENTER
  • COMBINATION
  • PLACEBO
  • ARRY-142886
  • DABRAFENIB

Cite this